Pfizer, BioNTech: Phase 3 Study Shows High Efficacy of Covid-19 Vaccine Booster
October 21 2021 - 6:49AM
Dow Jones News
By Colin Kellaher
Pfizer Inc. and BioNTech SE on Thursday said a Phase 3 study
showed a booster dose of their Covid-19 vaccine in individuals 16
years of age and older saw a relative vaccine efficacy of 95.6%
compared to those who didn't receive a booster.
The partners said a booster dose administered to those who had
already received the primary two-dose series of their vaccine
restored protection against Covid-19 to the high levels achieved
after the second dose.
Pfizer and BioNTech said they plan to submit the data to
regulatory agencies around the world to support licensure in the
U.S. and other countries.
The U.S. Food and Drug Administration in September granted
emergency approval of a third dose of the Pfizer/BioNTech vaccine
for people 65 and older and certain other adults at high risk of
severe illness. The agency Wednesday cleared the use of a booster
dose in eligible individuals who completed a primary round with a
different vaccine.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 21, 2021 07:34 ET (11:34 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
BioNTech (NASDAQ:BNTX)
Historical Stock Chart
From Apr 2024 to May 2024
BioNTech (NASDAQ:BNTX)
Historical Stock Chart
From May 2023 to May 2024